Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Oral Switch Therapy in Low-Risk Staphylococcus aureus Bloodstream Infection
2013-000577-77Phase 3Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of flucloxacillin in Staphylococcus aureus bloodstream infection (SABSI) and Staphylococcus aureus septicaemia (SAB) (2 arms), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: SAB-related complications. Started May 2013; status: completed.
02
Drugs
flucloxacillin
03
Conditions
Staphylococcus aureus bloodstream infection (SABSI)Staphylococcus aureus septicaemia (SAB)
Beyond the preview
Go deeper on 2013-000577-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000577-77.